Cancer cell lines representative of different cancer types and primary cancer specimens transfected or treated with NLRC5 coding nucleic acids will not only upregulate MHC-I expression but also APM genes that will facilitate processing and presentation of tumor antigenic peptides to boost the power of proteogenomic cancer neoantigen discovery. This evidence concerns the gene NLRC5 and cancer.